Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability

Authors not listed

Universitätsklinikum Hamburg-Eppendorf · 2011

Abstract

5-azacytidine treatment prolongs survival in patients with myelodysplastic syndrome (MDS), but does not cure the disease. Allogeneic stem cell transplantation is a curative treatment option but is associated with a high risk treatment-related morbidity and mortality. In the current trial allogeneic stem cell transplantation will be compared to 5-azacytidine only treatment according to donor availability in elderly patients with MDS (55-70 years).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-13 MST

Cite this

APA
Anonymous. (2011). Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability. <em>Universitätsklinikum Hamburg-Eppendorf</em>. https://clinicaltrials.gov/study/NCT01404741
Vancouver
Anonymous. Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability. Universitätsklinikum Hamburg-Eppendorf. 2011.
BibTeX
@misc{anon2011Compar, title = {Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability}, author = {Anonymous}, journal = {Universitätsklinikum Hamburg-Eppendorf}, year = {2011}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings